Skip to main content

Foghorn Therapeutics, Inc. (FHTX)

NASDAQ: FHTX · IEX Real-Time Price · USD
13.23 0.16 (1.22%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap498.28M
Revenue (ttm)995,000
Net Income (ttm)-85.22M
Shares Out36.94M
EPS (ttm)-3.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume374,630
Open13.20
Previous Close13.07
Day's Range12.88 - 14.09
52-Week Range8.01 - 28.27
Betan/a
AnalystsBuy
Price Target25.67 (+94.0%)
Est. Earnings DateNov 9, 2021

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule...

IndustryBiotechnology
IPO DateOct 23, 2020
Employees95
Stock ExchangeNASDAQ
Ticker SymbolFHTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is 25.67, which is an increase of 94.03% from the latest price.

Price Target
$25.67
(94.03% upside)
Analyst Consensus: Buy

News

Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression th...

2 weeks ago - GlobeNewsWire

Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9

3 weeks ago - GlobeNewsWire

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

-- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML)

1 month ago - GlobeNewsWire

Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

1 month ago - GlobeNewsWire

Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

2 months ago - GlobeNewsWire

Foghorn Therapeutics Appoints Ian Smith to its Board of Directors

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

4 months ago - GlobeNewsWire

Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?

Foghorn Therapeutics (FHTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 months ago - Zacks Investment Research

UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021

CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

6 months ago - GlobeNewsWire

Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021

CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

6 months ago - GlobeNewsWire

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

6 months ago - PRNewsWire

Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

6 months ago - GlobeNewsWire

U.S. IPO Week Ahead: 6 IPOs Squeeze In Before The Thanksgiving Holiday

US IPO market activity is picking back up ahead of the Thanksgiving holiday, with six IPOs scheduled to raise $3.4 billion in the week ahead. Biotech research product provider Maravai LifeSciences plans...

Other symbols:GHLDMCFEMSPNARISLQT
10 months ago - Seeking Alpha

Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

10 months ago - GlobeNewsWire

Foghorn Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

10 months ago - GlobeNewsWire

Foghorn Therapeutics Files Terms For $120 Million IPO

Foghorn Therapeutics Files Terms For $120 Million IPO

10 months ago - Seeking Alpha

Foghorn Therapeutics sets IPO terms, to raise up to $127.5 million

Foghorn Therapeutics Inc. set terms for its initial public offering Monday, as the Massachusetts-based company focused on the chromatin regulatory system that leads to gene expression looks to raise up ...

10 months ago - Market Watch